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Wada Test Reliability (Response to Haber et al.) 
Tobias Loddenkemper MD, Harold H. Morris MD, Tara T. Lineweaver PhD, Christoph 
Kellinghaus MD 
To the Editors: 
We thank Dr. Haber and colleagues for their kind letter, and we are grateful for their comments. 
We also thank the editors for an opportunity to respond. 
 We agree with Dr. Haber that our results alone cannot support a strong conclusion about 
the statistical reliability of the Wada test. Our study was not specifically designed to test IAT 
reliability. Because of the retrospective study design, the two tests that were being compared on 
each patient differed in a number of respects (Loddenkemper et al., 2007b). In fact, as Haber and 
colleagues point out, failure of the first test was the most frequent trigger for the second test in 
our study. Even prospective studies may encounter similar difficulties due to ethical and 
procedural difficulties in the future. 
 Our conclusions in the last paragraph of our paper were drawn not only from our own 
results, but also from a review of the literature. This review included the experience from the 
South Florida Comprehensive Epilepsy Center including the authors of the letter to which we are 
responding (Benbadis and Heriaud, 2005). Interestingly, their abstract demonstrated the largest 
percentage change in repeated IAT memory test results without “confounding factors” reported 
to date (89%). Benbadis and Heriaud found “reversed memory test scores without obvious 
cause” in 9 cases. “Of 9 ‘reversed’ Wadas, 8 repeat tests were no longer ‘reversed,’” and this was 
interpreted as “significant test-retest variability for memory results.” We believe that their 
findings (which take into account confounding factors), together with our own (which show that 
most repeat IAT tests involve confounding factors), call into question the reliability of the 
memory part of the IAT. 
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 Haber et al. mention invalidity of the IAT as possibly limiting our ability to draw 
conclusions about its reliability. We would argue that invalidity of the IAT actually limits its 
reliability. Problems with the validity of the memory IAT have been discussed in detail in our 
manuscript. No gold standard for memory assessment–besides resection and subsequent 
amnesia–exists. Neuropsychological testing, fMRI, and IAT may all assess different aspects of 
memory and may therefore be hard to compare. “Validity” of the test may therefore be 
influenced by the observer. How to judge a trial as valid is unclear, particularly since, as Haber et 
al. state, “memory testing requires the sustained attention and participation of the patient…, and 
reactions to the various medications used in the Wada test can vary unpredictably.” With so 
much variability, it is difficult to determine whether a trial is valid. As a result, we would argue 
that clinicians should seriously question whether the result of an IAT memory test would be the 
same or different if repeated later. 
 We agree with Haber et al. that Brevital may be an alternative to amobarbital. However, 
Brevital injections bear the increased risk of more frequent seizures (Loddenkemper et al., 
2007a). Additionally, retesting with Brevital during a single catheterization will also require 
more time and more frequent injections. This prolonged interval and additional manipulations 
with an indwelling intraarterial catheter in place may also cause additional complications 
(Loddenkemper et al., 2002). 
 We appreciate Dr. Haber's comments about our paper and the opportunity to respond to 
them. Issues surrounding the IAT are important not only to us as clinicians, but also to our 
patients. We encourage further discussion of this test and future research addressing these 
questions. 
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